Dyadic Neurofeedback for Development of Healthy Emotion Regulation in Youth
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kara L Kerr, PhD
- Phone Number: 918-594-8242
- Email: kara.kerr@okstate.edu
Study Locations
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Hardesty Center for Clinical Research and Neuroscience
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All participants inclusion criteria:
- Biological female
- Sufficient English fluency to complete tasks
- Co-residing at least 4 days per week
Inclusion criteria for adult participants:
- Primary caregiver for more than 50% of child's lifespan
- History of at least two adverse childhood experiences
- Biological parent of adolescent participant
Inclusion criteria for adolescents:
- Eligible for fMRI
- Body mass index between 16 and 40 (inclusive)
- Age 14-17 years
Exclusion Criteria:
Exclusion criteria for adolescent participants:
- Current or past psychiatric disorder
- Neurodevelopmental delay
- Medications influencing fMRI
- Medical conditions influencing fMRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Neurofeedback Group
Mothers of adolescent participants will view real-time fMRI neurofeedback representing activity in their daughter's anterior insula during an emotion discussion task.
Activity will be presented as a colored bar of moving height, and mothers will be instructed to attempt to downregulate the activity through what they say to their daughter.
|
Real-time functional magnetic resonance imaging dyadic neurofeedback
|
|
No Intervention: Control Group
The paradigm for the control condition will be identical to that of the experimental condition except that no neurofeedback will be presented.
Participants in the control group will be told that we would like to see if the mother can regulate her daughter's brain activity through supportive statements.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Oxygen Level-Dependent (BOLD) signal changes (brain activation)
Time Frame: One hour (measured during one scan session)
|
Activation in the right anterior insular cortex and associated regions.
We hypothesize that lower activity will indicate a better outcome.
|
One hour (measured during one scan session)
|
|
Resting-state network activity
Time Frame: One year (change from first scan session to one-year follow-up)
|
Brain activity during fMRI resting-state scan
|
One year (change from first scan session to one-year follow-up)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive symptoms (change over time)
Time Frame: One year (change from first scan session to one-year follow-up)
|
Change over time in adolescent's responses to the PROMIS (Patient Reported Outcome Measurement Information System) Pediatric Short Form Version 2 (Quinn et al., 2014).
This is an 8-item scale with scores ranging from 8-40, with higher scores indicating more depressive symptoms.
|
One year (change from first scan session to one-year follow-up)
|
|
Parenting behaviors (change over time)
Time Frame: One year (change from first scan session to one-year follow-up)
|
Change over time in adolescent's responses to the Children's Report of Parent Behavior Inventory (Schludermann & Schludermann, 1988).
The CRPBI has 3 subscales, each with a score range of 10-30.
Interpretation/valence of the scores varies by subscale.
|
One year (change from first scan session to one-year follow-up)
|
|
Emotion regulation (change over time)
Time Frame: One year (change from first scan session to one-year follow-up)
|
Change over time in adolescent's responses to the Difficulties in Emotion Regulation Scale (Gratz & Roemer, 2008).
The DERS consists of 36 items rated on a 1-5 Likert scale (scale range: 36-180).
Higher scores indicate greater difficulties with emotion regulation.
|
One year (change from first scan session to one-year follow-up)
|
|
Parent-adolescent interaction quality (change over time)
Time Frame: Two weeks
|
Adolescents will complete ecological momentary assessment (EMA) measures multiple times per day over a period of two weeks and report on emotions experienced during interactions with their mother.
The ratio of positive to negative interactions across the EMA period will be calculated.
|
Two weeks
|
|
Affect variability (change over time)
Time Frame: Two weeks
|
Adolescents will complete ecological momentary assessment (EMA) measures multiple times per day over a period of two weeks and rate their current emotions at the time of the prompt.
Affect variability will be quantified as the standard deviation in mean negative emotion ratings.
|
Two weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kara L Kerr, PhD, Oklahoma State University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022029-Hardesty
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.